PMP22
Peripheral myelin protein 22
Also known as: CMT1A, GAS3, HMSNIA, HNPP, PMP22_HUMAN, Sp110
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q01453
- Gene
- PMP22
- Ensembl
- ENSG00000109099
- Chromosome
- 17
- Canonical length
- 160 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
This gene encodes an integral membrane protein that is a major component of myelin in the peripheral nervous system. Studies suggest two alternately used promoters drive tissue-specific expression. Various mutations of this gene are causes of Charcot-Marie-Tooth disease Type IA, Dejerine-Sottas syndrome, and hereditary neuropathy with liability to pressure palsies. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
160 residues, UniProt reviewed canonical sequence.
>Q01453|PMP22
1 MLLLLLSIIV LHVAVLVLLF VSTIVSQWIV GNGHATDLWQ NCSTSSSGNV HHCFSSSPNE
61 WLQSVQATMI LSIIFSILSL FLFFCQLFTL TKGGRFYITG IFQILAGLCV MSAAAIYTVR
121 HPEWHLNSDY SYGFAYILAW VAFPLALLSG VIYVILRKRELocalizationUniProt · AlphaFold · HPA
Whether an antibody against PMP22 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 4
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 246 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 246 nTPM
- spinal cord: 230 nTPM
- small intestine: 225 nTPM
- urinary bladder: 195 nTPM
- placenta: 190 nTPM
- colon: 187 nTPM
Single-cell type
- schwann cells: 1,578 nCPM
- hofbauer cells: 1,290 nCPM
- enterocytes: 1,064 nCPM
- fibroblasts: 459 nCPM
- melanocytes: 443 nCPM
- decidual stromal cells: 388 nCPM
Immune cell
- eosinophil: 43 nTPM
- basophil: 32 nTPM
- plasmacytoid DC: 24 nTPM
- myeloid DC: 7.6 nTPM
- classical monocyte: 1.4 nTPM
- intermediate monocyte: 0.9 nTPM
Brain region
- white matter: 311 nTPM
- medulla oblongata: 213 nTPM
- basal ganglia: 202 nTPM
- cerebellum: 191 nTPM
- midbrain: 171 nTPM
- pons: 165 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PMP22.
Disease | AllUniProt
Conditions PMP22 is implicated in, by any mechanism.
- Charcot-Marie-Tooth disease, demyelinating, type 1A (CMT1A) MIM:118220
- Dejerine-Sottas syndrome (DSS) MIM:145900
- Hereditary neuropathy with liability to pressure palsies (HNPP) MIM:162500
- Charcot-Marie-Tooth disease, demyelinating, type 1E (CMT1E) MIM:118300
- Inflammatory demyelinating polyneuropathy (IDP) MIM:139393
Disease | GeneticClinVar
104 pathogenic / likely-pathogenic of 433 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Charcot-Marie-Tooth disease, type I
- Charcot-Marie-Tooth disease
- Charcot-Marie-Tooth disease, type IA
- Dejerine-Sottas disease
- Hereditary liability to pressure palsies
ReferencesPubMed · IEDB
Publications for PMP22 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
4 publications
- Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy.
2009 · J Neurol Neurosurg Psychiatry · RCR 1.6 · 52 citations - Immune responses to myelin proteins in Guillain-Barré syndrome.
2008 · J Neurol Neurosurg Psychiatry · RCR 1.3 · 45 citations - Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies.
2000 · J Neuroimmunol · RCR 1.3 · 49 citations - Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a).
2002 · J Neurol Neurosurg Psychiatry · RCR 1 · 35 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.39
- gnomAD pLI
- 0.91
- gnomAD missense Z
- 0.42
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- bleb assembly
- cell differentiation
- chemical synaptic transmission
- myelin assembly
- negative regulation of cell population proliferation
- negative regulation of neuron projection development
- peripheral nervous system development
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PMP22 as an antibody target. Whether an autoantibody or antibody against PMP22 could matter depends on whether native PMP22 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PMP22 is annotated at the cell surface, where native PMP22 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label PMP22 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...